Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis

Not Applicable

Completed

• Conditions: Chronic Rhinitis
• Interventions: Device: ClariFix Device

• Registration Number: NCT03181594
• Lead Sponsor: Arrinex, Inc.

Brief Summary

A multi-center, prospective, non-randomized, interventional clinical trial to assess the safety and effectiveness of the ClariFix™ device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-02
• Study First Submitted: 2017-06-07
• Study First Submitted QC: 2017-06-07
• Study First Posted: 2017-06-09
• Primary Completion: 2018-07-31
• Results First Submitted: 2019-10-15
• Results First Submitted QC: 2019-10-15
• Results First Posted: 2019-11-04
• Study Completion: 2020-04-06
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-25
• Last Update Posted: 2021-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Subject is >21 years of age
2. Subject has moderate to severe symptoms of rhinorrhea (individual symptom rating of 2 or 3), mild to severe symptoms of congestion (individual symptom rating of 1, 2 or 3) and a minimum TNSS score of 4 (out of 12) at the time of the treatment visit, which have been present for > 6 months.
3. Subject has had documented allergy test within the last 10 years that defines whether or not subject has allergies to perennial and seasonal allergens or is willing to have one performed prior to study exit.
4. Subject has been dissatisfied with medical management, defined as usage of intranasal steroids for a minimum of 4 weeks without adequate symptom relief by the subject's assessment.
5. Subject has signed IRB-approved informed consent form

Exclusion Criteria

1. Subject has clinically significant anatomic obstructions that in the investigator's opinion limit access to the posterior nose, including but not limited to septal deviation or perforation, nasal polyps, sinonasal tumor.
2. Subject has had any prior sinus or nasal surgery that significantly alters the anatomy of the posterior nose.
3. Subject has active nasal or sinus infection.
4. Subject has moderate to severe ocular symptoms.
5. Subject has a history of nosebleeds in the past 3 months.
6. Subject has a history of rhinitis medicamentosa.
7. Subject has had prior head or neck irradiation
8. Subject has active coagulation disorder or is receiving anti-coagulants which cannot be safely stopped for 4 weeks (excluding aspirin).
9. Subject is pregnant.
10. Subject is participating in another clinical research study.
11. Subject has an allergy or intolerance to anesthetic agent.
12. Subject has cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and/or, open and/or infected wounds at or near the target tissue.
13. Any physical condition that in the investigator's opinion would prevent adequate study participation or pose increased risk.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment with the ClariFix Device	ClariFix Device	Bilateral ablation of nasal tissue for treatment of chronic rhinitis

Primary Outcome Measures

Name	Time	Method
Device- and/or Procedure-related Serious Adverse Events	90 days post treatment	Safety will be evaluated based on the frequency of device- and/or procedure-related serious adverse events
Change From Baseline in Symptom Severity	90 days post treatment	Effectiveness will be assessed by the mean change in nasal symptoms using the 4-symptom rTNSS (reflective Total Nasal Symptom Score). The rTNSS is the sum of 4 individual patient-rated symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, and 3=Severe. The rTNSS has a possible score of 0-12. The reflective scores are based on the participant's evaluation of symptom severity over the preceding 24 hours. A change of 1 or more is considered the minimum clinically important difference.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)	90 days post treatment	The RQLQ is a validated quality of life questionnaire that evaluates functional problems associated with rhinitis. The questionnaire assess 7 domains: activities, sleep, nose symptoms, eye symptoms, non nose/eye symptoms, practical problems, and emotional function. Each question is scores on a 7-point scale (0=not impaired at all, 6=severely impaired). A domain and total scores are based on the mean of all answered items in that domain resulting in domain or total scores ranging from 0 to 6. An average change on 0.5 or more is considered a minimal clinically important difference.

Trial Locations

Locations (6)

Sacramento Ear, Nose, and Throat; 🇺🇸 Sacramento, California, United States

California Sleep Institute; 🇺🇸 East Palo Alto, California, United States

San Francisco Otolaryngology Medical Group; 🇺🇸 San Francisco, California, United States

EVMS Otolaryngology; 🇺🇸 Norfolk, Virginia, United States

Ear, Nose, and Throat Associates of South Florida; 🇺🇸 Boca Raton, Florida, United States

Bethlehem Ear, Nose, and Throat; 🇺🇸 Bethlehem, Pennsylvania, United States